Research programme: skin disorder therapeutics - AstraZeneca/Galderma
Latest Information Update: 16 Jul 2016
At a glance
- Originator AstraZeneca; Galderma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acne; Atopic dermatitis; Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Acne in France
- 16 Jul 2016 No recent reports of development identified for research development in Atopic-dermatitis in France
- 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in France